Axium Healthcare Pharmacy Inc., a wholly-owned subsidiary of The Kroger Company and nationwide provider of specialty pharmacy services, announced that it has been accepted into the GlaxoSmithKline (GSK) Oncology network.

As a GSK-authorised specialty pharmacy, Axium will expand its long-standing oncology therapy management focus with the addition of the following GSK oral oncology specialty medications: Hycamtin (topotecan) capsules, Mekinis (trametinib) tablets, Tafinlar (dabrafenib) capsules, Promacta (eltrombopag) tablets, Tykerb (lapatinib) tablets, Votrient (pazopanib) tablets.

“We are pleased to be a part of the GSK Oncology Network,” said Axium Healthcare Pharmacy president and chief executive officer, Mark Montgomery. “For years, Axium Healthcare Pharmacy’s OncologyVisions programme has made it easier for patients and providers around the country to achieve better outcomes in cancer care. As an authorised GSK Oncology Network specialty pharmacy, Axium is well-positioned to provide practices and patients with the highly-personalised care, clinical support and ongoing patient management we’ve become known for.”